CY2063B1 - Hydroxymethyl(methylenecyclopentyl)purines and pyrimidines - Google Patents

Hydroxymethyl(methylenecyclopentyl)purines and pyrimidines

Info

Publication number
CY2063B1
CY2063B1 CY9802063A CY9802063A CY2063B1 CY 2063 B1 CY2063 B1 CY 2063B1 CY 9802063 A CY9802063 A CY 9802063A CY 9802063 A CY9802063 A CY 9802063A CY 2063 B1 CY2063 B1 CY 2063B1
Authority
CY
Cyprus
Prior art keywords
methylenecyclopentyl
purines
pyrimidines
hydroxymethyl
chem
Prior art date
Application number
CY9802063A
Other languages
English (en)
Inventor
Robert Zahler
William A Slusarchyk
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24400159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2063(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of CY2063B1 publication Critical patent/CY2063B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Tires In General (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CY9802063A 1990-10-18 1998-06-12 Hydroxymethyl(methylenecyclopentyl)purines and pyrimidines CY2063B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59956890A 1990-10-18 1990-10-18

Publications (1)

Publication Number Publication Date
CY2063B1 true CY2063B1 (en) 1998-06-12

Family

ID=24400159

Family Applications (2)

Application Number Title Priority Date Filing Date
CY9802063A CY2063B1 (en) 1990-10-18 1998-06-12 Hydroxymethyl(methylenecyclopentyl)purines and pyrimidines
CY2006008C CY2006008I2 (el) 1990-10-18 2014-09-29 Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2006008C CY2006008I2 (el) 1990-10-18 2014-09-29 Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines

Country Status (27)

Country Link
US (1) US5206244A (fr)
EP (1) EP0481754B1 (fr)
JP (1) JP2994117B2 (fr)
KR (1) KR0160523B1 (fr)
CN (1) CN1030916C (fr)
AT (1) ATE157095T1 (fr)
AU (1) AU634423B2 (fr)
BR (1) BR1100846A (fr)
CA (1) CA2053339C (fr)
CY (2) CY2063B1 (fr)
DE (3) DE69127336T2 (fr)
DK (1) DK0481754T3 (fr)
ES (1) ES2104673T3 (fr)
FI (1) FI109905B (fr)
GR (1) GR3025395T3 (fr)
HU (1) HU213207B (fr)
IE (1) IE913451A1 (fr)
IL (1) IL99755A (fr)
LU (1) LU91275I2 (fr)
NL (1) NL300241I1 (fr)
NO (2) NO179906C (fr)
NZ (1) NZ240053A (fr)
PL (1) PL169403B1 (fr)
PT (1) PT99281B (fr)
RU (1) RU2037496C1 (fr)
SG (1) SG70958A1 (fr)
ZA (1) ZA917894B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221816B1 (hu) * 1991-10-11 2003-01-28 Bristol-Myers Squibb Pharma Company Gyűrűs karbonil vegyületek, és ezeket tartalmazó gyógyászati készítmények
EP0630897A3 (fr) * 1993-06-25 1995-03-01 Bristol Myers Squibb Co 3-Hydroxy-4-hydroxyméthyl-2-methylène-cyclopentyl purines et pyrimidines.
EP0770621A4 (fr) * 1994-07-12 1998-01-28 Yamasa Corp 2'-desoxy-2'-(methylidene substitue ou non substitue)-4'-thionucleoside
WO1996019478A1 (fr) * 1994-12-19 1996-06-27 Novartis Ag Nucleosides carbocycliques substitues en position 6'
GB9520363D0 (en) * 1995-10-05 1995-12-06 Chiroscience Ltd Compounds
WO1998009964A1 (fr) * 1996-09-03 1998-03-12 Bristol-Myers Squibb Company PROCEDE DE PREPARATION AMELIORE DE L'AGENT ANTIVIRAL [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENE-CYCLOPENTYL]-6-H-PURINE-6-ONE
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
CN100387237C (zh) * 1998-08-10 2008-05-14 艾丹尼克斯(开曼)有限公司 用于治疗乙型肝炎的β-L-2'-脱氧-核苷
US6432966B2 (en) * 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
CN1813753B (zh) * 2000-02-29 2010-04-07 布里斯托尔-迈尔斯斯奎布公司 低剂量艾替开韦制剂及其应用
EE05442B1 (et) * 2000-02-29 2011-08-15 Bristol-Myers Squibb Company V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks
US20020056123A1 (en) * 2000-03-09 2002-05-09 Gad Liwerant Sharing a streaming video
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
US7153691B2 (en) * 2002-11-13 2006-12-26 G6 Science Corp. Method of identifying and assessing DNA euchromatin in biological cells for detecting disease, monitoring wellness, assessing bio-activity, and screening pharmacological agents
CN101899063B (zh) * 2002-12-11 2012-12-12 布里斯托尔-迈尔斯斯奎布公司 制备抗病毒药[1S-(1α,3α,4β)]-2-氨基-1,9-二氢-9-[4-羟基-3-(羟甲基)-2-亚甲环戊基]-6H-嘌呤-6-酮的方法
US7511139B2 (en) * 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
TW200540175A (en) * 2004-06-04 2005-12-16 Bristol Myers Squibb Co Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
CN100379736C (zh) * 2005-05-13 2008-04-09 上海仲夏化学有限公司 恩替卡韦的制备方法
CN1699366A (zh) * 2005-06-03 2005-11-23 北京市典范科技有限责任公司 嘌呤衍生物
CN1907987B (zh) * 2005-08-03 2010-05-05 江苏正大天晴药业股份有限公司 恩地卡韦酸加成盐及其制备方法和用途
US20070060599A1 (en) * 2005-09-09 2007-03-15 Dimarco John D Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
CN101016299B (zh) * 2006-02-09 2010-05-12 北京典范科技有限责任公司 制备嘌呤衍生物的新方法
CN101130542B (zh) * 2006-08-24 2010-08-04 江苏正大天晴药业股份有限公司 抗病毒核苷类似物的合成方法
CN101210015B (zh) * 2006-12-26 2010-09-22 上海国创医药有限公司 一种乙肝治疗药物恩替卡韦的制备方法
CN101245068A (zh) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
CN101074217B (zh) * 2007-04-04 2010-11-24 北京精华耀邦医药科技有限公司 通过制备色谱分离得到高纯度恩替卡韦关键中间体的方法
AU2008265397C1 (en) 2007-06-18 2013-08-29 Sunshine Lake Pharma Co., Ltd. Bromo-phenyl substituted thiazolyl dihydropyrimidines
US20090076038A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched entecavir
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
TW201026715A (en) * 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
JP6104504B2 (ja) * 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー ヌクレオシド類似体
KR101150254B1 (ko) 2008-12-26 2012-06-12 한미사이언스 주식회사 신규 중간체 및 이를 활용한 엔테카비르 제조방법
CN101531660B (zh) * 2009-04-14 2012-07-04 安徽贝克联合制药有限公司 一种恩替卡韦一水合物的工业化生产工艺
CA2777018C (fr) * 2009-10-12 2014-04-29 Hanmi Holdings Co., Ltd. Nouveau procede de preparation d'entecavir et ses intermediaires
US9700560B2 (en) * 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
CN101759698B (zh) * 2009-12-15 2012-01-18 上海医药集团股份有限公司 一种恩替卡韦的制备方法
US8481728B2 (en) * 2010-02-16 2013-07-09 Scinopharm Taiwan, Ltd. Process for preparing entecavir and its intermediates
CL2011000716A1 (es) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
CA2705953C (fr) * 2010-05-31 2018-05-01 Alphora Research Inc. Synthese de carbanucleoside et composes intermediaires utiles pour la synthese
EP2474548A1 (fr) 2010-12-23 2012-07-11 Esteve Química, S.A. Procédé de préparation d'un médicament antiviral et ses intermédiaires
EP2508172A1 (fr) 2011-04-06 2012-10-10 Zentiva, a.s. Formulations stables et uniformes d'entecavir et procédé de préparation correspondant
CN102491960A (zh) * 2011-11-16 2012-06-13 福建广生堂药业股份有限公司 一种合成恩替卡韦的中间体及其制备方法和应用
EP2597096A1 (fr) 2011-11-24 2013-05-29 Esteve Química, S.A. Procédé de préparation d'entecavir et intermédiaires associés
CN103304375B (zh) * 2012-03-12 2017-04-12 浙江奥翔药业股份有限公司 恩替卡韦的合成中间体及其制备方法
EP2846788A1 (fr) 2012-05-11 2015-03-18 Akron Molecules AG Utilisation de composés pour le traitement de la douleur
WO2014068265A1 (fr) 2012-10-29 2014-05-08 Cipla Limited Analogues de phosphonate antiviraux et leur procédé de préparation
WO2015014737A1 (fr) 2013-07-29 2015-02-05 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations pour comprimés multicouches comprenant du tenofovir et de l'entécavir
WO2015051900A1 (fr) 2013-10-08 2015-04-16 Pharmathen S.A. Procédé de préparation d'entécavir au moyen de nouveaux intermédiaires
KR101640504B1 (ko) * 2015-04-15 2016-07-18 동방에프티엘(주) 엔테카비르 일수화물의 제조방법
KR101640503B1 (ko) * 2015-04-15 2016-07-18 동방에프티엘(주) 엔테카비르 일수화물의 개선된 제조방법
WO2018092728A1 (fr) * 2016-11-16 2018-05-24 国立研究開発法人国立国際医療研究センター Dérivé nucléosidique ayant des activités physiques comprenant une activité antivirale
CN108203435B (zh) * 2016-12-16 2020-09-04 正大天晴药业集团股份有限公司 一种利用Boc保护基的恩替卡韦的制备方法
CN106749251A (zh) * 2017-01-17 2017-05-31 博瑞生物医药泰兴市有限公司 一种恩替卡韦中间体的合成与提纯方法
KR102197257B1 (ko) * 2017-10-19 2020-12-31 단국대학교 천안캠퍼스 산학협력단 엔테카비어 지방산 에스테르 유도체 수성현탁액의 안정화 조성물
CN109956975B (zh) * 2017-12-22 2020-11-06 浙江柏拉阿图医药科技有限公司 肝递送恩替卡韦前体药物核苷环磷酸酯化合物及应用
AU2019398792A1 (en) * 2018-12-12 2021-06-10 Janssen Biopharma, Inc. Cyclopentyl nucleoside analogs as anti-virals
CN113024574B (zh) * 2019-12-25 2024-03-29 南通诺泰生物医药技术有限公司 一种氧杂二环己烷类化合物的制备方法
CN111732589B (zh) * 2020-06-08 2021-07-30 王乔 一种改进的恩替卡韦中间体合成工艺以及改进的恩替卡韦合成工艺
CN112625041A (zh) * 2020-12-25 2021-04-09 常州博海威医药科技股份有限公司 恩替卡韦的新制备方法以及中间体
US20240299557A1 (en) * 2021-01-22 2024-09-12 Taibidi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Compound for degrading deoxyribonucleic acid (dna) polymerase, and use thereof
CN115433188B (zh) * 2022-09-29 2024-07-12 苏州东瑞制药有限公司 一种恩替卡韦的制备方法
CN115819422A (zh) * 2022-12-13 2023-03-21 淄博矿业集团有限责任公司 恩替卡韦中间体制备新工艺方法及分析方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164556B (fr) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US5063233A (en) * 1986-11-14 1991-11-05 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives useful as adenosine receptor agonists
US5047520A (en) * 1987-03-19 1991-09-10 Yamasa Shoyu Kabushiki Kaisha 2'-alkylidenepyrimidine nucleoside derivatives, process for production thereof, and uses thereof
NZ225906A (en) * 1987-08-26 1990-10-26 Merrell Dow Pharma Aristeromycin/adenosine derivatives and pharmaceutical compositions
US4997925A (en) * 1987-08-26 1991-03-05 Merrell Dow Pharmaceuticals Inc. 5'-deoxy-5',5'-dihalo adenosines and purine analogues
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
ES2057031T3 (es) * 1988-08-25 1994-10-16 Yoshitomi Pharmaceutical Compuestos de nucleosido de 2'-metilidenpirimidina, su uso y metodo para su produccion.
HU204843B (en) * 1988-09-27 1992-02-28 Merrell Dow Pharma Process for producing 2'-halogen-methylidene adenosine derivatives and pharmaceutical compositions comprising same
GB8916478D0 (en) * 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
US5064961A (en) * 1989-12-18 1991-11-12 E. R. Squibb & Sons, Inc. Process for preparing an optically active cyclobutane nucleoside
US5057630A (en) * 1990-04-06 1991-10-15 Glaxo Inc. Synthesis of cyclopentene derivatives

Also Published As

Publication number Publication date
DE69127336T2 (de) 1998-01-02
US5206244A (en) 1993-04-27
NO179906B (no) 1996-09-30
EP0481754A3 (en) 1992-09-16
PL292101A1 (en) 1992-08-10
KR920008043A (ko) 1992-05-27
JP2994117B2 (ja) 1999-12-27
PT99281B (pt) 1999-04-30
NL300241I1 (nl) 2006-12-01
SG70958A1 (en) 2000-03-21
NO914089L (no) 1992-04-21
RU2037496C1 (ru) 1995-06-19
HU913283D0 (en) 1992-01-28
ATE157095T1 (de) 1997-09-15
CA2053339C (fr) 2001-05-29
CY2006008I1 (el) 2009-11-04
NO914089D0 (no) 1991-10-17
LU91275I2 (fr) 2007-06-16
FI914928L (fi) 1992-04-19
EP0481754B1 (fr) 1997-08-20
DE122006000069I2 (de) 2012-04-19
CY2006008I2 (el) 2016-10-05
ZA917894B (en) 1993-03-31
HU213207B (en) 1997-03-28
CA2053339A1 (fr) 1992-04-19
AU634423B2 (en) 1993-02-18
NO2006018I1 (no) 2006-12-27
GR3025395T3 (en) 1998-02-27
CN1030916C (zh) 1996-02-07
FI914928A0 (fi) 1991-10-18
CN1061972A (zh) 1992-06-17
BR1100846A (pt) 2000-04-18
EP0481754A2 (fr) 1992-04-22
IL99755A0 (en) 1992-08-18
HK1001343A1 (en) 1998-06-12
NZ240053A (en) 1993-05-26
ES2104673T3 (es) 1997-10-16
FI109905B (fi) 2002-10-31
NO2006018I2 (no) 2008-10-20
JPH04282373A (ja) 1992-10-07
AU8559891A (en) 1992-04-30
PT99281A (pt) 1992-08-31
HUT59109A (en) 1992-04-28
DK0481754T3 (da) 1997-09-15
IL99755A (en) 1996-08-04
DE69127336D1 (de) 1997-09-25
NO179906C (no) 1997-01-08
KR0160523B1 (ko) 1998-12-01
DE122006000069I1 (de) 2007-05-24
IE913451A1 (en) 1992-04-22
PL169403B1 (pl) 1996-07-31

Similar Documents

Publication Publication Date Title
GR3025395T3 (en) Hydroxymethyl(methylenecyclopentyl)Purines and Pyrimidines
DK724088D0 (da) Purinyl- pyrimidinylcyclobutaner
NZ228645A (en) 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
IL118367A0 (en) Heteroaroyl derivatives
AU616839B2 (en) Purinyl and pyrimidinyl tetrahydrofurans
EP0464769A3 (en) Purinyl and pyrimidinyl tetrahydrofurans
EP0352013A3 (fr) Hydroxyméthyl cyclobutylepurines